- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
- Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
More ▼
Key statistics
On Friday, Sarepta Therapeutics Inc (SRPT:NSQ) closed at 133.66, -16.41% below its 52-week high of 159.89, set on May 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 132.55 |
---|---|
High | 134.47 |
Low | 131.16 |
Bid | 128.00 |
Offer | 134.90 |
Previous close | 130.63 |
Average volume | 1.26m |
---|---|
Shares outstanding | 94.51m |
Free float | 89.90m |
P/E (TTM) | 1,677.67 |
Market cap | 12.63bn USD |
EPS (TTM) | 0.0797 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼